138 related articles for article (PubMed ID: 27288034)
1. Efficacy and tolerability of ethionamide versus prothionamide: a systematic review.
Scardigli A; Caminero JA; Sotgiu G; Centis R; D'Ambrosio L; Migliori GB
Eur Respir J; 2016 Sep; 48(3):946-52. PubMed ID: 27288034
[No Abstract] [Full Text] [Related]
2. [Current questions in the treatment of patients with chronic destructive pulmonary tuberculosis].
Mamolat AS; Bialik IB; Khutorskaia VD
Klin Med (Mosk); 1976 Dec; 54(12):72-8. PubMed ID: 189127
[No Abstract] [Full Text] [Related]
3. [Therapeutic efficiency of ethionamide and prothionamide].
Kozulitsyna TI; Zemskova ZS
Probl Tuberk; 1969; 47(8):66-9. PubMed ID: 5375685
[No Abstract] [Full Text] [Related]
4. A comparison of therapeutic efficacy and toxicity of ethionamide and prothionamide in Indian patients.
Gupta DK; Mital OP; Agarwal MC; Kansal HM; Nath S
J Indian Med Assoc; 1977 Jan; 68(2):25-9. PubMed ID: 326974
[No Abstract] [Full Text] [Related]
5. [Bacteriostatic activity of blood in single and combined use of ethionamide or prothionamide].
Kozulitsyna TI; Korotaev GA
Probl Tuberk; 1975; (5):70-3. PubMed ID: 1144350
[No Abstract] [Full Text] [Related]
6. [Comparative clinical study of prothionamide and ethionamide in the treatment of pulmonary tuberculosis].
Shmelev NA; Korotaev GA; Poleshchuk AK; Utkin VV; Golitsyna LV
Probl Tuberk; 1969; 47(1):27-33. PubMed ID: 5380204
[No Abstract] [Full Text] [Related]
7. Metabolism of the antituberculosis drug ethionamide.
Vale N; Gomes P; Santos HA
Curr Drug Metab; 2013 Jan; 14(1):151-8. PubMed ID: 23215813
[TBL] [Abstract][Full Text] [Related]
8. A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy.
Fajardo TT; Guinto RS; Cellona RV; Abalos RM; Dela Cruz EC; Gelber RH
Am J Trop Med Hyg; 2006 Mar; 74(3):457-61. PubMed ID: 16525107
[TBL] [Abstract][Full Text] [Related]
9. Further data on the effect of ethionamide and prothionamide in experimental leprosy.
Pattyn SR
Lepr Rev; 1978 Sep; 49(3):199-202. PubMed ID: 692251
[No Abstract] [Full Text] [Related]
10. Drugs for combined therapy: experimental studies on the antileprosy activity of ethionamide and prothionamide, and a general review.
Colston MJ; Ellard GA; Gammon PT
Lepr Rev; 1978 Jun; 49(2):115-26. PubMed ID: 661479
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results.
Singla R; Gupta S; Gupta R; Arora VK
Int J Tuberc Lung Dis; 2001 Jun; 5(6):559-63. PubMed ID: 11409584
[TBL] [Abstract][Full Text] [Related]
12. [Principles underlying the use of antituberculosis medication in children (author's transl)].
Ollivier A; Besson-Leaud M
Sem Hop; 1979 Oct 8-15; 55(33-34):1529-35. PubMed ID: 229564
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients.
Rao NA; Irfan M; Soomro MM; Mehfooz Z
J Coll Physicians Surg Pak; 2010 Apr; 20(4):262-5. PubMed ID: 20392404
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
Prasad R; Verma SK; Sahai S; Kumar S; Jain A
Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
[TBL] [Abstract][Full Text] [Related]
15. Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
Choi J; Park SJ; Jee JG
Eur J Med Chem; 2015 Dec; 106():157-66. PubMed ID: 26544630
[TBL] [Abstract][Full Text] [Related]
16. A review of the use of ethionamide and prothionamide in childhood tuberculosis.
Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
Tuberculosis (Edinb); 2016 Mar; 97():126-36. PubMed ID: 26586647
[TBL] [Abstract][Full Text] [Related]
17. Prothionamide Dose Optimization Using Population Pharmacokinetics for Multidrug-Resistant Tuberculosis Patients.
Yun HY; Chang MJ; Jung H; Chang V; Wang Q; Strydom N; Yoon YR; Savic RM
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0189321. PubMed ID: 35938799
[TBL] [Abstract][Full Text] [Related]
18. Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis.
Vale N; Correia A; Silva S; Figueiredo P; Mäkilä E; Salonen J; Hirvonen J; Pedrosa J; Santos HA; Fraga A
Bioorg Med Chem Lett; 2017 Feb; 27(3):403-405. PubMed ID: 28057421
[TBL] [Abstract][Full Text] [Related]
19. Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis.
Schaaf HS; Victor TC; Venter A; Brittle W; Jordaan AM; Hesseling AC; Marais BJ; van Helden PD; Donald PR
Int J Tuberc Lung Dis; 2009 Nov; 13(11):1355-9. PubMed ID: 19861006
[TBL] [Abstract][Full Text] [Related]
20. Prothionamide.
Tuberculosis (Edinb); 2008 Mar; 88(2):139-40. PubMed ID: 18486054
[No Abstract] [Full Text] [Related]
[Next] [New Search]
